Harpoon Therapeutics Inc

NASDAQ:HARPUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Contact Information

Headquarters

131 Oyster Point Blvd Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-1910

Phone

650-443-7400

Fax

302-636-5454

Executives

Non-Executive Chairman of the Board, Independent Director

Scott Myers

President, Chief Executive Officer, Director

Julie Eastland

Principal Financial Officer, Principal Accounting Officer

Frank Lanza

Senior Vice President - Human Resources

Wendy Chang

Senior Vice President - Translational Medicine

Banmeet Anand